DNA methylation of CHFR is not a predictor of the response to docetaxel and paclitaxel in advanced and recurrent gastric cancer

Anticancer Research

Volumn 26, Issue 1 A, 2006, Pages 49-54

  Yoshida, Kazuhiro ^a   Hamai, Yoichi ^a   Suzuki, Takahisa ^a   Sanada, Yuichi ^a   Oue, Naohide ^b   Yasui, Wataru ^b  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

Author keywords

CHFR; DNA methylation; Docetaxel; Gastric cancer; Paclitaxel

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; BISULFITE; DOCETAXEL; MESSENGER RNA; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CELL CYCLE; CHFR GENE; CLINICAL ARTICLE; DNA METHYLATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; GENE; HUMAN; HUMAN TISSUE; MALE; MITOSIS; PREDICTION; PRIORITY JOURNAL; RECURRENT CANCER; RESTRICTION MAPPING; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL CYCLE PROTEINS; CPG ISLANDS; DNA METHYLATION; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; OXONIC ACID; PACLITAXEL; PYRIDINES; RETROSPECTIVE STUDIES; RNA, MESSENGER; STOMACH NEOPLASMS; TAXOIDS; TEGAFUR;

EID: 32144440317     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Yoshida K, Hirabayashi N, Takiyama W, Ninomiya M, Takakura N, Sakamoto J, Nishiyama M and Toge T: Phase I study of combination therapy with S-1 and docetaxel (TXT) for advanced or recurrent gastric cancer. Anticancer Res 24: 1843-1851, 2004.
2. Longley DB and Johnston PG: Molecular mechanisms of drug resistance. J Pathol 205: 275-292, 2005.
3. Lamendola DE, Duan Z, Yusuf RZ and Seiden MV: Molecular description of evolving paclitaxel resistance in the SKOV-3 human ovarian carcinoma cell line. Cancer Res 63: 2200-2205, 2003.
4. Kikuchi T, Daigo Y, Katagiri T, Tsunoda T, Okada K, Kakiuchi S, Zembutsu H, Furukawa Y, Kawamura M, Kobayashi K, Imai K and Nakamura Y: Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph-node metastasis and sensitivity to anticancer drugs. Oncogene 22: 2192-2205, 2003.
5. Yasui W, Oue N, Ono S, Mitani Y, Ito R and Nakayama H: Histone acetylation and gastrointestinal carcinogenesis. Ann N Y Acad Sci 983: 220-231, 2003.
6. Oue N, Hamai Y, Mitani Y, Matsumura S, Oshimo Y, Aung PP, Kuraoka K, Nakayama H and Yasui W: Gene expression profile of gastric carcinoma: identification of genes and tags potentially involved in invasion metastasis and carcinogenesis by serial analysis of gene expression. Cancer Res 64: 2397-2405, 2004.
7. Jones PA and Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428, 2002.
8. Ushijima T and Okochi-Takada E: Aberrant methylations in cancer cells: where do they come from? Cancer Sci 96: 206-211, 2005.
9. Toyota M, Ahuja N, Suzuki H, Itoh F, Ohe-Toyota M, Imai K, Baylin SB and Issa JP: Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res 59: 5438-5442, 1999.
10. Kaneda A, Kaminishi M, Yanagihara K, Sugimura T and Ushijima T: Identification of silencing of nine genes in human gastric cancers. Cancer Res 62: 6645-6650, 2002.
11. Oue N, Motoshita J, Yokozaki H, Hayashi K, Tahara E, Taniyama K, Matsusaki K and Yasui W: Distinct promoter hypermethylation of p16INK4a CDH1 and RAR-beta in intestinal diffuse-adherent and diffuse-scattered type gastric carcinomas. J Pathol 198: 55-59, 2002.
12. Rashid A and Issa JP: CpG island methylation in gastroenterologic neoplasia: a maturing field. Gastroenterology 727: 1578-1588, 2004.
13. Scolnick DM and Halazonetis TD: Chfr defines a mitotic stress checkpoint that delays entry into metaphase. Nature 406: 430-435, 2000.
14. Matsusaka T and Pines J: Chfr acts with the p38 stress kinases to block entry to mitosis in mammalian cells. J Cell Biol 166: 507-516, 2004.
15. Yu X, Minter-Dykhouse K, Malureanu L, Zhao WM, Zhang D, Merkle CJ, Ward IM, Saya H, Fang G, van Deursen J and Chen J: Chfr is required for tumor suppression and Aurora A regulation. Nat Genet 37: 401-406, 2005.
16. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW and Vogelstein B: Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 104: 263-269, 1999.
17. Suzuki H, Itoh F, Toyota M, Kikuchi T, Kakiuchi H and Imai K: Inactivation of the 14-3-3 sigma gene is associated with 5′ CpG island hypermethylation in human cancers. Cancer Res 60: 4353-4357, 2000.
18. Satoh A, Toyota M, Itoh F, Sasaki Y, Suzuki H, Ogi K, Kikuchi T, Mita H, Yamashita T, Kojima T, Kusano M, Fujita M, Hosokawa M, Endo T, Tokino T and Imai K: Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer. Cancer Res 63: 8606-8613, 2003.
19. Mizuno K, Osada H, Konishi H, Tatematsu Y, Yatabe Y, Mitsudomi T, Fujii Y and Takahashi T: Aberrant hypermethylation of the CHFR prophase checkpoint gene in human lung cancers. Oncogene 21: 2328-2333, 2002.
20. Honda T, Tamura G, Waki T, Kawata S, Nishizuka S and Motoyama T: Promoter hypermethylation of the Chfr gene in neoplastic and non-neoplastic gastric epithelia. Br J Cancer 90: 2013-2016, 2004.
21. Herman JG, Graff JR, Myohanen S, Nelkin BD and Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93: 9821-9826, 1996.
22. Xiong Z and Laird PW: COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res 25: 2532-2534, 1997.
23. Kondo T, Oue N, Yoshida K, Mitani Y, Naka K, Nakayama H and Yasui W: Expression of POT1 is associated with tumor stage and telomere length in gastric carcinoma. Cancer Res 64: 523-529, 2004.
24. Rudolph KL, Millard M, Bosenberg MW and DePinho RA: Telomere dysfunction and evolution of intestinal carcinoma in mice and humans. Nat Genet 28: 155-159, 2001.
25. Shigeishi H, Yokozaki H, Oue N, Kuniyasu H, Kondo T, Ishikawa T and Yasui W: Increased expression of CHK2 in human gastric carcinomas harboring p53 mutations. Int J Cancer 99: 58-62, 2002.
26. Shigeishi H, Oue N, Kuniyasu H, Wakikawa A, Yokozaki H, Ishikawa T and Yasui W: Expression of Bub1 gene correlates with tumor proliferating activity in human gastric carcinomas. Pathobiology 69: 24-29, 2001.